The FDA has granted approval for the use of encorafenib in combination with cetuximab and mFOLFOX6 for the treatment of ...

This past year, the role of ctDNA testing has expanded to guide treatment decisions for providers and patients with cancer.

From detecting early disease to guiding treatment plans, clinicians are finding ctDNA testing increasingly important.

Ensartinib has received FDA approval for the first-line treatment of ALK-positive locally advanced or metastatic non–small ...

FDA gives nod of approval to first derived mesenchymal stromal cell therapy for the treatment of pediatric patients with ...

Pharmacologic strategies may be able to prevent abnormal uterine bleeding in patients undergoing stem cell transplant.

Panelists discuss how Brandi first noticed symptoms leading to her paroxysmal nocturnal hemoglobinuria (PNH) diagnosis, highlighting the challenges of the initial diagnostic process, and explore the ...

Treatment with subcutaneous daratumumab significantly improved progression-free survival in patients with intermediate- or ...

Treatment with tafasitamab for relapsed/refractory DLBCL in the United States was supported by data from a retrospective ...

Long-term follow-up showed continued meaningful responses in patients with relapsed or refractory KMT2Ar acute leukemia who ...

According to real-world data, no survival advantage was seen when comparing 3 frontline CDK4/6 inhibitor combinations in ...

An expanded analysis from the phase 3 CEPHEUS trial showed that daratumumab plus VRd improved MRD responses as well as ...